Education
About Us
Working with TipRanks
Follow Us
MDxHealth (MDXH)
NASDAQ:MDXH
MDXH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.35 - $3.50
Previous CloseN/A
Volume27.23K
Average Volume (3M)68.64K
Market Cap
$102.71M
Enterprise Value$105.83M
Total Cash (Recent Filing)$46.80M
Total Debt (Recent Filing)$60.06M
Price to Earnings (P/E)―
Beta-1208.98
Next Earnings
Aug 14, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding49,497,334
10 Day Avg. Volume58,609
30 Day Avg. Volume68,642
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)6.16
Price to Sales (P/S)0.00
P/FCF Ratio-4.31
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue0.32
Enterprise Value/Gross Profit1.96
Enterprise Value/Ebitda-1.39
Forecast
1Y Price Target
$6.00Price Target Upside189.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
MDxHealth News
PremiumCompany Announcements
MDxHealth Schedules Second EGM for Share Option Plan Approval
PremiumCompany Announcements
MDxHealth Earnings Call: Growth Amid Financial Challenges
PremiumCompany Announcements
MDxHealth Reports Strong Q1 2025 Revenue Growth
PremiumCompany Announcements
MDxHealth Reports Strong Financial Turnaround in 2024Bulls Say, Bears Say
Bulls Say
Financial PerformanceMDx Health is on track to achieve its AEBITDA positivity milestone, which is critical to de-risking the model further.
Market ValuationShares of MDXH trade at just 0.8x our 2026 rev estimate of $128M, below small cap peers at 2.0x, and MDXH is primed to achieve multiple expansion.
Product GrowthThe volume of tissue-based tests grew by more than 40% year-over-year, driven by a successful go-to-market strategy.
Bears Say
Gross Margin ConcernsGross margin of 62.7% declined Y/Y due to timing and test mix, and expanded ~150bp Q/Q.
Price Target AdjustmentThe price target was adjusted from $7.00 to $5.00, indicating a more conservative outlook.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.09%
Mutual Funds
41.28% Other Institutional Investors
58.64% Public Companies and Individual Investors
MDXH FAQ
What was MDxHealth’s price range in the past 12 months?
MDxHealth lowest stock price was $1.35 and its highest was $3.50 in the past 12 months.
What is MDxHealth’s market cap?
MDxHealth’s market cap is $102.71M.
When is MDxHealth’s upcoming earnings report date?
MDxHealth’s upcoming earnings report date is Aug 14, 2025 which is in 67 days.
How were MDxHealth’s earnings last quarter?
MDxHealth released its earnings results on May 14, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.06.
Is MDxHealth overvalued?
According to Wall Street analysts MDxHealth’s price is currently Undervalued.
Does MDxHealth pay dividends?
MDxHealth does not currently pay dividends.
What is MDxHealth’s EPS estimate?
MDxHealth’s EPS estimate is -0.12.
How many shares outstanding does MDxHealth have?
MDxHealth has 49,497,334 shares outstanding.
What happened to MDxHealth’s price movement after its last earnings report?
MDxHealth reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went up 6.742%.
Which hedge fund is a major shareholder of MDxHealth?
Currently, no hedge funds are holding shares in MDXH
MDxHealth Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (189.86% Upside)
$6.00 (189.86% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.59%
12-Months-Change
Fundamentals
Return on Equity
-1552.23%
Trailing 12-Months
Asset Growth
43.61%
Trailing 12-Months
Company Description
MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
MDXH Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance by MDxHealth, with consistent revenue growth driven by tissue-based tests and improved gross margins. However, challenges remain with increased net loss and the impact of a significant earn-out payment. Overall, the company's strategic positioning and future outlook appear positive, but financial losses present ongoing challenges.Read More>MDXH Stock 12 Month Forecast
Average Price Target
$6.00
▲(189.86%Upside)